over basal values was observed in cardiac output, stroke volume, and dp/dt. Heart rate increased only moderately. Systemic and pulmonary vascular resistances diminished, without appreciable change in aortic or pulmonary mean pressures.
The haemodynamic effects of isoprenaline were investigated in IO patients with acute myocardial infarction. Serial measurements of multiple parameters at increasing concentrations of the drug allowed establishment of a dose-response curve.
Significant increase over basal values was observed in cardiac output, stroke volume, and dp/dt. Heart rate increased only moderately. Systemic and pulmonary vascular resistances diminished, without appreciable change in aortic or pulmonary mean pressures.
These results were obtained with concentrations of 2/3 to tg/min. No arrhythmias were induced and the clinical tolerance was uniformly good.
The use of these small doses of isoprenaline and their effectiveness in the management of myocardial failure complicating infarction are particularly emphasized. Patients with major complications such as severe arrhythmias, cardiogenic shock, or advanced right heart failure were excluded from this study. The selected patients had not received inotropic or vasoactive agents for the previous two weeks.
Informed consent was obtained from each patient and his attending physician after proper description of the procedure and its aims. FIG. 4 Measurement of aortic dp/dt at increasing doses of isoprenaline in 9 patients. (Fig. 2) .
Stroke output increased 20 per cent, from a mean control of 66 ml to 79 ml at 2 ,ug/ min, with subsequent drop at a higher infusion rate. In fact, practically 8o per cent of the cases had their maximal response at the 23 jig/min level (Fig. 3) , though the values are of borderline statistical significance. The dp/dt changed from an average basal value of i645 to 2645 with i jxg/min, representing a significant augmentation of 6o per cent (Fig. 4) . Systemic vascular resistance diminished by 34 per cent during maximal infusion rates (Fig. 5) , while pulmonary vascular resistance decreased 37 per cent at a similar concentration of isoprenaline (Fig. 6) .
No arrhythmias were induced throughout the investigation, and the clinical tolerance was uniformly good. Discussion A number of agents have been used for their inotropic properties in acute myocardial infarction complicated by congestive heart failure or cardiogenic shock. The use of digitalis, though the best known of these agents, is limited by an increased risk of intoxication due to a reduced threshold at the onset of severe rhythm disturbances. This has been observed in man (Selzer, I968) , and clearly documented in the experimental animal (Bellet, Johnston, and Schechter, 1934; Travell, Gold, and Modell, I938; Morris et al., I969) . Furthermore, patients during the acute stage of a myocardial infarction may require defibrillation as a form of management of primary life-threatening arrhythmias, and this procedure is more hazardous in the presence of digitalization (Kleiger and Lown, I966) .
The use of non-glycoside agents such as glucagon (Warembourg et al., I969; Puri and Bing, I969; Murtagh et al., I970; Parmley and Sonnenblick, 1971) or dopamine (Talley et al., I969) can still be considered to be in an experimental phase.
The pharmacological properties of isoprenaline, leading to an increase in cardiac output, diminution of peripheral vascular resistance, improved perfusion of vital organs, and little change in mean pulmonary or systemic pressures (Kaufman, Iglauer, and Her- It may be concluded that isoprenaline, apart from its value as an adjunct in the management of patients with hypotension or shock, may find application in the treatment of congestive heart failure, particularly if initial heart rates are not too high. As shown by a concentration-response curve, this can be achieved with relatively small doses and with avoidance of untoward effects.
